Literature DB >> 30937995

Upper gastrointestinal bleeding in Egyptian patients with cirrhosis: Post-therapeutic outcome and prognostic indicators.

Tamer R Fouad1, Eman Abdelsameea1, Wael Abdel-Razek1, Ahmed Attia1, Anwar Mohamed1, Khaled Metwally1, Mary Naguib2, Imam Waked1.   

Abstract

BACKGROUND AND AIM: Upper gastrointestinal bleeding (UGIB) is a serious complication of portal hypertension in cirrhotic patients. The objective of this study is to identify the risk factors for morbidity and mortality occurring after an UGIB attack.
METHODS: A total of 1097 UGIB attacks in 690 patients with liver cirrhosis were studied. Their clinical, laboratory, and endoscopic data were reviewed.
RESULTS: Mean age 53.2 ± 10.6 (20-90) years, 78% men and the main cause of liver disease was hepatitis C (94.9%). Complications occurred after 467 attacks (42.6%): hepatic encephalopathy 31.4%, spontaneous bacterial peritonitis 18%, renal impairment 13.2%, and re-bleeding in 7.8%, while 199 patients (18.1%) died. Complications followed 78.4% of bleeding from gastric varices, 75% of post-interventional ulcers, 10.8% of peptic ulcers, and 5.9% of telangiectasias. By univariate analysis: packed red blood cells units transfused, transaminases, Child-Pugh (CP), model of end-stage liver disease (MELD), and albumin-bilirubin (ALBI) scores, beside the presence of hepatocellular carcinoma (HCC), previous hemorrhage in the previous 6 months, and the source of bleeding, were associated with occurrence of complications. By multivariate analysis, independent predictors of complications were CP, MELD, and ALBI scores (odds ratio, 95% confidence interval: 5.63, 3.55-8.93; 1.15, 1.11-1.19; and 2.11, 1.4-3.19, respectively) beside the presence of HCC (4.89, 2.48-9.64). Mortality predictors were packed red blood cells units transfused (1.11, 1.01-1.24), CP (5.1, 1.42-18.25) MELD (1.27, 1.21-1.32) scores, and presence of HCC (6.62, 2.93-14.95).
CONCLUSION: High CP, MELD, and ALBI scores beside the presence of HCC could predict poor outcome of UGIB. In the absence of these risk factors, early discharge could be considered if the source of bleeding is peptic ulcer or telangiectasia.
© 2019 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  ALBI score; MELD; cirrhosis; upper gastrointestinal bleeding

Mesh:

Year:  2019        PMID: 30937995     DOI: 10.1111/jgh.14659

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  6 in total

1.  Comparing the Performance of the ABC, AIMS65, GBS, and pRS Scores in Predicting 90-day Mortality Or Rebleeding Among Emergency Department Patients with Acute Upper Gastrointestinal Bleeding: A Prospective Multicenter Study.

Authors:  Shuang Liu; Xiaoming Zhang; Joseph Harold Walline; Xuezhong Yu; Huadong Zhu
Journal:  J Transl Int Med       Date:  2021-06-16

2.  Immature Granulocyte Count and Percentage as New Predictors of Mortality in Patients with Upper Gastrointestinal Bleeding.

Authors:  Cihan Bedel; Mustafa Korkut; Ali Avcı; Ahmet Uzun
Journal:  Indian J Crit Care Med       Date:  2020-09

3.  The role of refined nursing combined with targeted nursing in patients with digestive tract hemorrhages complicated by liver cirrhosis.

Authors:  Yan Wang; Yanna Wang; Junping Han
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

4.  The effect of pantoprazole and somatostatin combined with thrombin in the treatment of non-esophagogastric varicosity upper gastrointestinal bleeding.

Authors:  Yu Duan; Ji Chen; Hong Cui; Cuijuan Zhao
Journal:  Am J Transl Res       Date:  2021-05-15       Impact factor: 4.060

5.  Fresh Frozen Plasma in Cases of Acute Upper Gastrointestinal Bleeding Does Not Improve Outcomes.

Authors:  Shuang Liu; Xiaoming Zhang; Joseph Harold Walline; Xuezhong Yu; Huadong Zhu
Journal:  Front Med (Lausanne)       Date:  2022-07-14

6.  Intravenous Drip of Somatostatin Followed by Restricted Fluid Resuscitation to Treat Upper Gastrointestinal Bleeding in Patients with Liver Cirrhosis.

Authors:  Xuni He; Zhuhua Dai; Peina Shi; Jiemin Hong
Journal:  Evid Based Complement Alternat Med       Date:  2021-10-13       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.